Newswire (Published: Friday, April 12, 2019, Received: Friday, April 12, 2019, 4:17:43 PM CDT)

Word Count: 540

2019 APR 12 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news reporting out of Shanghai, People’s Republic of China, by NewsRx editors, research stated, “Risk prediction models including the Prostate Health Index (phi) for prostate cancer have been well established and evaluated in the Western population. The aim of this study is to build phi-based risk calculators in a prostate biopsy population and evaluate their performance in predicting prostate cancer (PCa) and high-grade PCa (Gleason score {{>=}}7) in the Chinese population.”

Our news journalists obtained a quote from the research from the University of Fudan, “We developed risk calculators based on 635 men who underwent initial prostate biopsy. Then, we validated the performance of prostate-specific antigen (PSA), phi, and the risk calculators in an additional observational cohort of 1045 men. We observed that the phi-based risk calculators (risk calculators 2 and 4) outperformed the PSA-based risk calculator for predicting PCa and high-grade PCa in the training cohort. In the validation study, the area under the receiver operating characteristic curve (AUC) for risk calculators 2 and 4 reached 0.91 and 0.92, respectively, for predicting PCa and high-grade PCa, respectively; the AUC values were better than those for risk calculator 1 (PSA-based model with an AUC of 0.81 and 0.82, respectively) (all p<0.001). Such superiority was also observed in the stratified population with PSA ranging from 2.0 ng mlto 10.0 ng ml. Decision curves confirmed that a considerable proportion of unnecessary biopsies could be avoided while applying phi-based risk calculators. In this study, we showed that, compared to risk calculators without phi, phi-based risk calculators exhibited superior discrimination and calibration for PCa in the Chinese biopsy population.”

According to the news editors, the research concluded: “Applying these risk calculators also considerably reduced the number of unnecessary biopsies for PCa.”

For more information on this research see: Phi-based risk calculators performed better in the prediction of prostate cancer in the Chinese population. Asian Journal of Andrology, 2019;0(0):0. Asian Journal of Andrology can be contacted at: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA. (Nature Publishing Group -; Asian Journal of Andrology -

Our news journalists report that additional information may be obtained by contacting Y.S. Wu, Dept. of Urology, HuaShan Hospital, University of Fudan, Shanghai 200040, People’s Republic of China. Additional authors for this research include X.J. Fu, R. Na, D.W. Ye, J. Qi, X.L. Lin, F. Liu, J. Gong, N. Zhang, G.L. Jiang, H.W. Jiang, Q. Ding, J. Xu and Y.H Sun.

The direct object identifier (DOI) for that additional information is: This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the Asian Journal of Andrology is: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)


Eastern Asia
North America
People's Republic of China
United States


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
Life and Society
      Social Issues